8-K: Ekso Bionics Reports Steep Q2 Revenue Decline Amid Sales Delays

Ekso Bionics Holdings, Inc. announced significantly lower second-quarter 2025 revenue and increased net loss, primarily due to short-term delays in Enterprise Health device sales, despite growth in Personal Health products and strategic AI initiatives.

Summary

• Revenue for the second quarter of 2025 was $2.1 million, a significant decrease from $5.0 million in the same period of 2024.
• Gross profit for Q2 2025 was $0.8 million, down from $2.6 million in Q2 2024, with gross margin falling to approximately 40% from 53%.
• Net loss applicable to common stockholders for Q2 2025 increased to $2.7 million, or $1.24 per basic and diluted share, compared to a net loss of $2.4 million, or $1.99 per basic and diluted share, for Q2 2024.
• For the six months ended June 30, 2025, revenue was $5.4 million, down from $8.7 million in the first half of 2024.
• Net loss for the six months ended June 30, 2025, was $5.6 million, compared to $5.8 million for the same period in 2024.
• Cash and restricted cash stood at $5.2 million as of June 30, 2025, a decrease from $6.5 million as of December 31, 2024.
• Sales and marketing expenses decreased to $1.7 million in Q2 2025 from $1.8 million in Q2 2024, primarily due to lower discretionary payroll expense.
• Research and development expenses decreased to $0.9 million in Q2 2025 from $1.1 million in Q2 2024, primarily due to lower headcount.
• General and administrative expenses increased to $2.3 million in Q2 2025 from $2.0 million in Q2 2024, primarily due to lower allocable costs to manufacturing.
• Personal Health products grew by more than 50% year-over-year in the first half of 2025.

Sentiment

Score: 3

Explanation: The financial results show significant underperformance with a steep decline in revenue and gross profit, and an increased net loss. While there are positive strategic developments and growth in a specific product line, the overall financial health for the quarter is concerning, leading to a low sentiment score.

Positives

• Named Bionic Prosthetics & Orthotics Group (Bionic P&O) as the first Ekso Indego Personal device distributor within the orthotics and prosthetics industry.
• Accepted into the NVIDIA Connect program, supporting a new strategic initiative to build a proprietary foundation model for human motion and integrate new artificial intelligence (AI) capabilities.
• Announced initial proof-of-concept for a new AI voice agent (Ekso Voice Agent) designed for intelligent control of the legacy EksoNR device.
• Launched eksoUniversity, a new platform offering continuing education courses for physical therapists and physical therapy assistants.
• Personal Health products demonstrated strong growth, increasing by more than 50% year-over-year in the first half of 2025.
• Experienced a reduction in service costs, partially offsetting the decrease in gross profit.
• Sales and marketing expenses decreased due to lower discretionary payroll expense.
• Research and development expenses decreased due to lower headcount.
• Reported a significant unrealized gain on foreign exchange of $1.3 million in Q2 2025.

Negatives

• Revenue for Q2 2025 significantly decreased to $2.1 million from $5.0 million in Q2 2024, primarily due to lower sales of Enterprise Health devices.
• Gross profit declined to $0.8 million in Q2 2025 from $2.6 million in Q2 2024, with gross margin decreasing to 40% from 53%.
• The decrease in gross margin was driven by fixed costs of goods in relation to decreased Enterprise Health device sales, lower margin sales related to increased volume through distribution, and an increase in shipping costs.
• Net loss applicable to common stockholders increased to $2.7 million in Q2 2025 from $2.4 million in Q2 2024.
• General and administrative expenses increased to $2.3 million in Q2 2025 from $2.0 million in Q2 2024, primarily due to lower allocable costs to manufacturing.
• Cash and restricted cash decreased to $5.2 million as of June 30, 2025, from $6.5 million as of December 31, 2024.
• Accounts receivable, net, decreased to $4.5 million as of June 30, 2025, from $7.2 million as of December 31, 2024.

Risks

• Inability to obtain adequate financing to fund and grow operations and develop/enhance technology.
• Inability to successfully collaborate with existing neuro-rehabilitation facilities, physicians, and DMEs in seeking CMS reimbursements.
• Inability to obtain future reimbursements from CMS in a timely manner and at expected reimbursement levels.
• Inability to obtain insurance coverage beyond CMS.
• Inability to obtain additional indications of use for devices.
• Uncertain timing of executing sales contracts with large hospital networks.
• Significant length of time and resources associated with the development of products.
• Failure to achieve broad market acceptance of products.
• Failure of sales and marketing efforts or of partners to market products effectively.
• Adverse results in future clinical studies of medical device products.
• Failure to obtain or maintain patent protection for technology.
• Failure to obtain or maintain regulatory approval to market medical devices.
• Lack of product diversification.
• Existing or increased competition.
• Disruptions in the supply chain.
• Failure to implement business plans or strategies.

Future Outlook

Management expects to recover in the second half of 2025 and beyond by completing deferred multi-device Enterprise Health sales, continuing to meet anticipated Enterprise Health customer demand, and increasing contributions from Personal Health products.

Management Comments

• "While there was abnormal weakness in the second quarter, in large part due to what we believe are short-term delays in completing some multi-device Enterprise Health sales, we are working to get back on track for the second half of the year and beyond."
• "In addition to pulling in those aforementioned sales deferrals and continuing to meet anticipated Enterprise Health customer demand, we expect that to be bolstered by an increasing contribution from our Personal Health products, which grew by more than 50% year-over-year in the first half of 2025."

Industry Context

Ekso Bionics operates in the specialized field of exoskeleton technology, serving both medical and industrial applications. The company's strategic move into AI, particularly with its NVIDIA Connect program acceptance and the development of an AI voice agent for human motion, aligns with broader industry trends towards integrating advanced robotics and artificial intelligence to enhance human capabilities and improve health outcomes. Its position as the only known exoskeleton company offering solutions for both paralysis and industrial job sites highlights its unique market diversification.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Negative impact due to significant revenue decline, increased net loss, and decreased cash position, potentially affecting share price and future investment returns.
• Employees: Research and development headcount was reduced, indicating potential job impacts in that department.
• Customers: Enterprise Health customers may experience delays in receiving multi-device sales, though the company aims to pull in these deferrals.
• Creditors: Decreased cash and accounts receivable could impact liquidity, though current liabilities are also down.

Next Steps

• Work to complete deferred multi-device Enterprise Health sales.
• Continue to meet anticipated Enterprise Health customer demand.
• Increase contribution from Personal Health products.
• Continue development and integration of new artificial intelligence capabilities across the product portfolio.

Key Dates

Recommendation

The company reported significantly weaker financial results for Q2 2025, with a substantial drop in revenue and gross profit, and an increased net loss. This underperformance is attributed to 'abnormal weakness' and 'short-term delays' in Enterprise Health sales. While the Personal Health segment shows strong growth and strategic initiatives in AI are promising, the immediate financial outlook is challenging. A 'hold' recommendation is appropriate for a seasoned investor, acknowledging the current financial headwinds and the need for the company to demonstrate its ability to 'get back on track' in the second half of the year as stated by management. A 'sell' might be considered by those with lower risk tolerance, but the strategic positives and management's stated plan for recovery suggest waiting for further developments before exiting.

Keywords

Exoskeleton, Robotics, Medical Devices, Rehabilitation, Industrial Exoskeletons, Artificial Intelligence, AI Voice Agent, EksoNR, Ekso Indego Personal, NVIDIA Connect, Financial Results, Q2 2025, Healthcare Technology